TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36988819

Group type: EXPERIMENTAL
Intervention: Uterine lavage procedure with genetically screened euploid blastocysts
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF) (implied control)
Number of subjects: 8
Study: 36988824

Group type: EXPERIMENTAL
Intervention: Partial-thickness non-advanced tunnel technique (TUN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TUN
Number of subjects: 29

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 29
Study: 36988936

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol, 100 000 IU loading dose, followed by 20 000 IU/week)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Number of subjects: 122
Study: 36989027

Group type: EXPERIMENTAL
Intervention: Electronic brief intervention
Number of subjects: 329

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 329
Study: 36989357

Group type: EXPERIMENTAL
Intervention: CAdVEC (ultralow dose, single intratumoral injection)
Number of subjects: 4
Study: 36989829

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (anti-PD1 and anti-CTLA4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 120
Study: 36989884

Group type: EXPERIMENTAL
Intervention: AK109 (anti-VEGFR2 monoclonal antibody)
Number of subjects: 40
Study: 36990111

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 239
Study: 36990125

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) using 22-gauge Franseen tip or 25-gauge fork-tip needles
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) for lymphoproliferative disease
Number of subjects: 100
Study: 36990211

Group type: EXPERIMENTAL
Intervention: Refined SCR score using two genes (AKR1C3 and TCL1A) and four clinical parameters (previous experience of rejection, previous transplantation, sex of recipient, tacrolimus uptake)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Refined SCR score validated in an external laboratory using qPCR and NanoString methods
Number of subjects: 588
Study: 36990214

Group type: EXPERIMENTAL
Intervention: Covered stent after PTA
Number of subjects: 280

Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 280
Study: 36990225

Group type: EXPERIMENTAL
Intervention: Nordic group (NG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 250
Study: 36990261

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) treatment
Number of subjects: 23121

Group type: COMPARATOR
Intervention: No oral anticoagulation (no-OAC) treatment
Number of subjects: 23121
Study: 36990275

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC; cPRO plus web-based symptom self-management intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC; cPRO alone)
Number of subjects: 0
Study: 36990274

Group type: EXPERIMENTAL
Intervention: Standard acupuncture (SA; up to 15 treatment sessions across 12 weeks)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Enhanced acupuncture (EA; SA during first 12 weeks and up to 6 additional sessions across the following 12 weeks)
Number of subjects: 807

Group type: COMPARATOR
Intervention: Usual medical care (UMC) alone
Number of subjects: 807
Study: 36990468

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Social support/education (SE)
Number of subjects: 78
Study: 36990469

Group type: EXPERIMENTAL
Intervention: Adults with ADHD
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64
Study: 36990475

Group type: EXPERIMENTAL
Intervention: VR-assisted cognitive behavioural therapy (VR-CBT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 102
Study: 36990482

Group type: EXPERIMENTAL
Intervention: Computerised diagnostic decision support systems (CDDS) used during diagnostic workup.
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Usual clinical care without access to CDDS during diagnostic workup.
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: CDDS usage during intervention periods.
Number of subjects: 1184
Study: 36990481

Group type: EXPERIMENTAL
Intervention: Cognitive fatigability
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Executive inhibition
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Imaging markers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Self-rated fatigue
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Verbal fluency
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study: 36990483

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (No CCT)
Number of subjects: 26
Study: 36990493

Group type: EXPERIMENTAL
Intervention: Dynamic risk prediction models incorporating adverse events and medications
Number of subjects: 23887

Group type: EXPERIMENTAL
Intervention: In-hospital percutaneous coronary intervention (PCI)
Number of subjects: 23887

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy and statins at discharge
Number of subjects: 23887

Group type: EXPERIMENTAL
Intervention: Age, prior stroke, heart rate, Killip class, left ventricular ejection fraction (LVEF), recurrent myocardial ischaemia, recurrent myocardial infarction, heart failure (HF) during hospitalisation
Number of subjects: 23887

Group type: EXPERIMENTAL
Intervention: Age, prior renal dysfunction, history of HF, AMI classification, heart rate, Killip class, haemoglobin, LVEF, in-hospital PCI, HF during hospitalisation, HF worsening within 30 days after discharge, antiplatelet therapy, β blocker and statin use within 30 days after discharge
Number of subjects: 23887
Study: 36990546

Group type: EXPERIMENTAL
Intervention: Hematopoietic somatic mosaicism (HSM) carriers
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HSM assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HSM carriers
Number of subjects: 104
Study: 36990554

Group type: COMPARATOR
Intervention: Standard planning
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CT + simulation-based planning
Number of subjects: 200
Study: 36990558

Group type: EXPERIMENTAL
Intervention: Navitor valve
Number of subjects: 260
Study: 36990576

Group type: EXPERIMENTAL
Intervention: Durvalumab after chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36990607

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36990609

Group type: EXPERIMENTAL
Intervention: Toripalimab combined with definitive chemoradiotherapy (50·4 Gy in 28 fractions, five cycles of weekly intravenous paclitaxel [50 mg/m²])
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Toripalimab combined with definitive chemoradiotherapy
Number of subjects: 42
Study: 36990608

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Non-steroidal antiandrogen (control)
Number of subjects: 1125
Study: 36990610

Group type: EXPERIMENTAL
Intervention: Endoscopic surveillance (initial endoscopy and subsequent endoscopies every 6 to 12 months)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Prophylactic total gastrectomy
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Follow-up of patients
Number of subjects: 270
Study: 36990622

Group type: EXPERIMENTAL
Intervention: Eprenetapopt (4·5 g/day on days 1-4) and venetoclax (400 mg/day on days 1-28) with azacitidine (75 mg/m2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Eprenetapopt and venetoclax with azacitidine
Number of subjects: 49
Study: 36990930

Group type: EXPERIMENTAL
Intervention: Muscadine grape extract supplement (MGES) - four tablets twice daily for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Muscadine grape extract supplement (MGES)
Number of subjects: 64
Study: 36991169

Group type: EXPERIMENTAL
Intervention: OCS-05 (0.05-3.2 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36991301

Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cholecystectomy after PC
Number of subjects: 195
Study: 36991380

Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training (EXE) three times per week throughout pregnancy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Motivational counselling on physical activity (MOT) seven times during pregnancy
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care (CON)
Number of subjects: 219
Study: 36991390

Group type: EXPERIMENTAL
Intervention: NEO-201 (1 mg/kg, 1.5 mg/kg, 2 mg/kg) administered intravenously every two weeks in a 28-day cycle until DLT, disease progression, or patient withdrawal.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NEO-201 treatment
Number of subjects: 17
Study: 36991396

Group type: EXPERIMENTAL
Intervention: 50 g of raisins daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 0
Study: 36991415

Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR) in high-output group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR) in normal-output group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR)
Number of subjects: 20
Study: 36991434

Group type: EXPERIMENTAL
Intervention: Facilitation intervention enabling care aides to lead quality improvement efforts over one year.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 64
Study: 36991450

Group type: EXPERIMENTAL
Intervention: 60 mg oral dextromethorphan hydrobromide preoperatively, 30 mg at 8 h and 16 h postoperatively
Number of subjects: 160

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 160
Study: 36991453

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing plus Substance-Free Activities Session plus Mindfulness (BSM)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both interventions (for non-adherent individuals)
Number of subjects: 280
Study: 36991460

Group type: EXPERIMENTAL
Intervention: Melanoma surveillance photography (MSP) in addition to routine clinical surveillance
Number of subjects: 580

Group type: COMPARATOR
Intervention: Routine clinical surveillance without MSP
Number of subjects: 580
Study: 36991490

Group type: EXPERIMENTAL
Intervention: Ready2Change-Methamphetamine (R2C-M) intervention, n = 98 ± 4; four to six telephone-delivered intervention sessions, R2C-M workbooks and MA information booklet
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Ready2Change-Methamphetamine (R2C-M) intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group, n = 98 ± 4; four to six ≤5-min telephone check-ins and MA information booklet including information on accessing further support
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 36991547

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously once weekly after two step-up doses (0.06 and 0.3 mg/kg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Teclistamab with tocilizumab for first CRS event
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Teclistamab without tocilizumab for first CRS event
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 165
Study: 36992530

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13523

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 13523
Study: 36992541

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: HIV+ with ID
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: HIV+
Number of subjects: 166

Group type: COMPARATOR
Intervention: HIV- and ID
Number of subjects: 166
Study: 36992590

Group type: EXPERIMENTAL
Intervention: Home-based computerized cognitive stimulation program (7 training sessions, 45 minutes each, over 15 days)
Number of subjects: 12
Study: 36992749

Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training (SMART) program conducted over 8 sessions via web-based video conference software
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training (SMART) program
Number of subjects: 0
Study: 36992761

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 102
Study: 36992863

Group type: EXPERIMENTAL
Intervention: 3 years of anastrozole (1 mg orally once a day)
Number of subjects: 1912

Group type: EXPERIMENTAL
Intervention: 6 years of anastrozole (1 mg orally once a day)
Number of subjects: 1912
Study: 36992865

Group type: EXPERIMENTAL
Intervention: Combining same prescriptions
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Pill dispenser
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Finish previous refills first
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control group (not combining same prescriptions)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Pharmacy-fill adherence
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 731
Study: 36992911

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Number of subjects: 0
Study: 36993265

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community Health Workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video Feedback at Family Meals
Number of subjects: 0
Study: 36993363

Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg, sc)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline (0.2 mL, sc)
Number of subjects: 62
Study: 36993496

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Oxygen mask
Number of subjects: 1300
Study: 36993617

Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Placebo infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 1544
Study: 36993880

Group type: EXPERIMENTAL
Intervention: Perinatal Mental Health for Refugee Women (PMH-RW) Project
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures on depression (EPDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures on anxiety (GAD-7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: City Birth Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact of events scale-revised (PTSD-R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-Item Personality Inventory-TIPI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socio-demographic questionnaire
Number of subjects: 0
Study: 36993886

Group type: EXPERIMENTAL
Intervention: 12-week mind-body based online intervention program consisting of 36 mind-body based micropractices
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: 12-week mind-body based online intervention program
Number of subjects: 643
Study: 36994205

Group type: EXPERIMENTAL
Intervention: Integrated whole-body
Number of subjects: 55
Study: 36994730

Group type: EXPERIMENTAL
Intervention: CSL112 infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 36994923

Group type: COMPARATOR
Intervention: Preventive zinc supplementation (zinc sulfate, 10-15 mg daily)
Number of subjects: 219584

Group type: COMPARATOR
Intervention: Preventive zinc supplementation
Number of subjects: 219584
Study: 36994947

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (lebrikizumab withdrawal)
Number of subjects: 0
Study: 36995416

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no instructions after initial assessment)
Number of subjects: 84
Study: 36995469

Group type: EXPERIMENTAL
Intervention: guselkumab (IL-23p19 subunit inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ustekinumab (IL-12/23p40 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: risankizumab (IL-23p19 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0
Study: 36995567

Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) during food-related reappraisal task
Number of subjects: 32
Study: 36995690

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CT-RT) in trial 9514
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Preoperative image-guided radiotherapy (RT) in trial 0630
Number of subjects: 143

Group type: COMPARATOR
Intervention: Pathologic complete response (pCR)
Number of subjects: 143
Study: 36995739

Group type: EXPERIMENTAL
Intervention: Health4Her (alcohol brief intervention + lifestyle information)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control (lifestyle information)
Number of subjects: 558
Study: 36995742

Group type: EXPERIMENTAL
Intervention: Tiling and Aggregation (T&A) algorithms applied to rPPG signals
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Control group (no T&A applied)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: T&A algorithms for darker skin tones
Number of subjects: 1315
Study: 36995743

Group type: EXPERIMENTAL
Intervention: eHealth tool (COPD Web)
Number of subjects: 10
Study: 36995872

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.04, 0.08, 0.16 mg/kg/week) for 1 year, followed by 0.16 mg/kg/week for 3 years
Number of subjects: 50

Group type: COMPARATOR
Intervention: Somapacitan (0.16 mg/kg/week) after switching from daily GH
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day) for 3 years, then somapacitan (0.16 mg/kg/week) for 1 year
Number of subjects: 50
Study: 36995971

Group type: EXPERIMENTAL
Intervention: Periodic limb movements in sleep
Number of subjects: 0
Study: 36996150

Group type: EXPERIMENTAL
Intervention: Acebilustat 100 mg/d for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acebilustat
Number of subjects: 60
Study: 36996185

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel with AP 10-701
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel without AP 10-701
Number of subjects: 60

Group type: COMPARATOR
Intervention: Euvax B hepatitis B vaccine (Control)
Number of subjects: 60
Study: 36996236

Group type: EXPERIMENTAL
Intervention: Dyadic adjustment
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Home-based involvement
Number of subjects: 157
Study: 36996239

Group type: EXPERIMENTAL
Intervention: LMCAD non-culprit group
Number of subjects: 429

Group type: COMPARATOR
Intervention: No LMCAD group
Number of subjects: 429
Study: 36996264

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 22055
Study: 36996322

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily and selpercatinib 80 mg twice daily
Number of subjects: 14
Study: 36996325

Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI) treatment for 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Persistent ctDNA at 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Change from detected to undetected ctDNA by 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ctDNA change
Number of subjects: 81
Study: 36996373

Group type: EXPERIMENTAL
Intervention: Sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months
Number of subjects: 80
Study: 36996380

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 1311

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus Abiraterone Acetate and Prednisone (AAP)
Number of subjects: 1311
Study: 36996413

Group type: EXPERIMENTAL
Intervention: Structured Mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 36996503

Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline 0.1%
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 36996634

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Untreated MS controls
Number of subjects: 39
Study: 36996664

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 36996864

Group type: EXPERIMENTAL
Intervention: RR-CHOP (Rituximab intensification on day 0 of the 1st cycle with R-CHOP-21)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: RR-CHOP
Number of subjects: 92
Study: 36996935

Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention
Number of subjects: 2414

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2414
Study: 36997069

Group type: EXPERIMENTAL
Intervention: Brodalumab (interleukin-17 pathway inhibitor)
Number of subjects: 0
Study: 36997247

Group type: EXPERIMENTAL
Intervention: Hepatica preoperative MR scan (MR-based volumetry, Couinaud segmentation, liver tissue characteristics and operative planning tool)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LiMAx test (hepatic functional capacity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36997252

Group type: EXPERIMENTAL
Intervention: mecobalamin (vitamin B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0